This study investigated the mechanism underlying electroacupuncture therapy for vascular dementia through electroacupuncture at the acupoints of Baihui （DU20）, Dazhui （DU14）, and bilateral Shenshu （BL23） in a ra...This study investigated the mechanism underlying electroacupuncture therapy for vascular dementia through electroacupuncture at the acupoints of Baihui （DU20）, Dazhui （DU14）, and bilateral Shenshu （BL23） in a rat model of vascular dementia produced by bilateral middle cerebral artery occlusion. Morris water maze test showed that electroacupuncture improved the learning ability of vascular dementia rats. Western blot assay revealed that the expression of p70 ribosomal protein S6 kinase and ribosomal protein S6 in vascular dementia rats was significantly increased after electroacupuncture, compared with the model group that was not treated with acupuncture. The average escape latency was also shortened after electroacupuncture, and escape strategies in the spatial probe test improved from edge and random searches, to linear and trending swim pathways. The experimental findings indicate that electroacupuncture improves learning and memory ability by up-regulating expression of p70 ribosomal protein S6 kinase and ribosomal protein S6 in the hippocampus of vascular dementia rats.展开更多
目的探讨在不同肿瘤细胞中核糖体S6蛋白激酶4(ribosomal protein S6 kinase 4,RSK4)的表达谱是否存在差异,以及预测可能存在的蛋白亚型及其生物学特性。方法提取神经胶质瘤细胞GL261、卵巢癌细胞ID8、乳腺癌细胞4T1和168FARN、结肠癌细...目的探讨在不同肿瘤细胞中核糖体S6蛋白激酶4(ribosomal protein S6 kinase 4,RSK4)的表达谱是否存在差异,以及预测可能存在的蛋白亚型及其生物学特性。方法提取神经胶质瘤细胞GL261、卵巢癌细胞ID8、乳腺癌细胞4T1和168FARN、结肠癌细胞mc38和CT26、胃癌细胞MFC和肺癌细胞LLC1的RNA,采用RT-PCR技术检测RSK4的表达及其剪接异构体,生物信息学分析RSK4的生物学特征及其功能。结果RT-PCR结果显示在GL261、4T1、mc38、CT26、MFC和LLC1中均表达RSK4,且不同的肿瘤细胞中表达了多个剪接异构体,开放阅读框分析RSK4可能至少编码11个蛋白亚型;二级结构分析显示,这些剪接异构体编码的蛋白亚型均由α-螺旋、延伸链、β-转角和无规则卷曲组成,且保守结构域均相同;蛋白互作网络富集分析显示,RSK4主要通过mTOR信号通路和突触持续增强等信号通路在核质和胞浆中发挥激酶的活性。结论RSK4在不同的肿瘤细胞中存在不同的表达谱,可能产生多种氮端不同的蛋白异构体,能够通过多种信号通路参与不同的生物学途径。展开更多
Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span>...Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span></sup></span>) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR<sup>+</sup>), human epidermal growth factor receptor 2 negative (HER2<sup><span style="white-space:nowrap;"><sup><span style="white-space:nowrap;">−</span></sup></span></sup>) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug.展开更多
基金supported by the National Natural Science Foundation of China, No. 81001541
文摘This study investigated the mechanism underlying electroacupuncture therapy for vascular dementia through electroacupuncture at the acupoints of Baihui （DU20）, Dazhui （DU14）, and bilateral Shenshu （BL23） in a rat model of vascular dementia produced by bilateral middle cerebral artery occlusion. Morris water maze test showed that electroacupuncture improved the learning ability of vascular dementia rats. Western blot assay revealed that the expression of p70 ribosomal protein S6 kinase and ribosomal protein S6 in vascular dementia rats was significantly increased after electroacupuncture, compared with the model group that was not treated with acupuncture. The average escape latency was also shortened after electroacupuncture, and escape strategies in the spatial probe test improved from edge and random searches, to linear and trending swim pathways. The experimental findings indicate that electroacupuncture improves learning and memory ability by up-regulating expression of p70 ribosomal protein S6 kinase and ribosomal protein S6 in the hippocampus of vascular dementia rats.
文摘目的探讨在不同肿瘤细胞中核糖体S6蛋白激酶4(ribosomal protein S6 kinase 4,RSK4)的表达谱是否存在差异,以及预测可能存在的蛋白亚型及其生物学特性。方法提取神经胶质瘤细胞GL261、卵巢癌细胞ID8、乳腺癌细胞4T1和168FARN、结肠癌细胞mc38和CT26、胃癌细胞MFC和肺癌细胞LLC1的RNA,采用RT-PCR技术检测RSK4的表达及其剪接异构体,生物信息学分析RSK4的生物学特征及其功能。结果RT-PCR结果显示在GL261、4T1、mc38、CT26、MFC和LLC1中均表达RSK4,且不同的肿瘤细胞中表达了多个剪接异构体,开放阅读框分析RSK4可能至少编码11个蛋白亚型;二级结构分析显示,这些剪接异构体编码的蛋白亚型均由α-螺旋、延伸链、β-转角和无规则卷曲组成,且保守结构域均相同;蛋白互作网络富集分析显示,RSK4主要通过mTOR信号通路和突触持续增强等信号通路在核质和胞浆中发挥激酶的活性。结论RSK4在不同的肿瘤细胞中存在不同的表达谱,可能产生多种氮端不同的蛋白异构体,能够通过多种信号通路参与不同的生物学途径。
文摘Abemaciclib (Verzerio<span style="white-space:nowrap;"><sup><span style="font-family:Verdana, Helvetica, Arial;white-space:normal;background-color:#FFFFFF;">®</span></sup></span>) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR<sup>+</sup>), human epidermal growth factor receptor 2 negative (HER2<sup><span style="white-space:nowrap;"><sup><span style="white-space:nowrap;">−</span></sup></span></sup>) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug.
